Galapagos and OncoArendi Therapeutics have entered into an exclusive agreement for the global development and commercialization of OncoArendi’s OATD-01, an investigational treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Lung diseases like IPF are characterized by increased activity of enzymes called…
Partnership to Advance in Testing OATD-01, Potential IPF Therapy
Use of the well-known anticoagulant therapy warfarin in people with idiopathic pulmonary fibrosis (IPF) is associated with reduced transplant-free survival, but direct oral anticoagulants (DOACs) are not, a study found. While…
I have never met a cohort of people more resilient than children. I am reminded of this every day in my career, as I am privileged to walk alongside families facing hardships and discuss with parents and caregivers how to help their children through difficult times. As a trained therapist,…
A real-world analysis found that idiopathic pulmonary fibrosis (IPF) patients with preserved lung function benefitted from treatment with Ofev (nintedanib) and Esbriet (pirfenidone) over three years. Despite untreated patients entering this study…
Lung cancer contributes to a poor prognosis in patients with idiopathic pulmonary fibrosis (IPF), a new study indicates. The finding suggests that healthcare professionals should monitor the development and progression of cancer in patients with IPF, given its negative impact on prognosis. The study, “Prognostic impact of malignant…
FibroGen’s experimental antifibrotic therapy pamrevlumab may be more effective than Esbriet (pirfenidone) and Ofev (nintedanib) at slowing disease progression in people with idiopathic pulmonary fibrosis (IPF), according to a review study. Combined data from eight clinical trials showed that all three therapies significantly…
Earlier this month, I wrote a column about mental health and therapy options available during the pandemic. Hopefully, I made a strong case for giving therapy a try if you have been hesitant. I will always encourage people to try it out, but I…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops in December, with the aim of empowering leaders to start non-profit organizations and research programs to help people with rare diseases. “The RareLaunch program is…
A photo of a bespectacled young boy, his red baseball cap slightly askew as he enjoys time outside, will be featured on the front cover of an upcoming calendar in the “Same But Different” contest to raise awareness about rare disorders. “A Lovely Day Out in Kew Gardens,”…
Many people around the world complain about the cold, dark winter months. This is even true for Canadians who “should” be used to the frigid temperatures our country experiences every year. I know more people dislike the cold than the heat, but cold weather doesn’t pose health risks to…
